Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

Dirk Zimmermann

General Manager, International

Joined Exact Sciences: 2022

Dirk Zimmermann has served as General Manager, International since May 2022 and previously served as head of international expansion. Prior to joining Exact Sciences, Mr. Zimmermann was with Biocartis, where he was heading corporate business development and was a member of the corporate executive team. Before joining Biocartis, he was responsible for the global diagnostics development organization at Qiagen, including the general management of the company’s sites in Boston and Manchester (UK). Mr. Zimmermann also served as global development lead at Roche Molecular Systems out of Switzerland and the U.S.

Mr. Zimmermann holds a PhD in experimental biophysics and an executive MBA from the IMD in Lausanne (Switzerland) and held non-executive director positions at supervisory boards of both diagnostics and medical device companies in the U.S., Switzerland, and China.